<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04598984</url>
  </required_header>
  <id_info>
    <org_study_id>2506</org_study_id>
    <nct_id>NCT04598984</nct_id>
  </id_info>
  <brief_title>The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer</brief_title>
  <official_title>The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been shown that adipokines (resistin, leptin, adiponectin) secreted from adipose&#xD;
      tissue and proinflammatory cytokines such as IL-6, TNF-a are associated with the risk of&#xD;
      developing colorectal cancer. However, the role of these factors in predicting clinical&#xD;
      response to neoadjuvant therapy in rectal cancers is unknown. In this study, the role of&#xD;
      serum adipokine levels before neoadjuvant therapy in predicting clinical response in patients&#xD;
      with rectal cancer is investigated. For this purpose, blood will be drawn from patients with&#xD;
      rectal cancer who will receive neoadjuvant therapy, serum adipokines will be studied and&#xD;
      clinical response to neoadjuvant therapy will be compared.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients with Rectal Cancer</measure>
    <time_frame>1 year</time_frame>
    <description>The Adiponectin, Adipsin, Leptin, Resistin levels will be measured with flow cytometric analysis.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rectal Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>Low levels of serum adipokines</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>High levels of serum adipokines</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum adipokines</intervention_name>
    <description>Level of serum adipokines will be measured with flow cytometry</description>
    <arm_group_label>High levels of serum adipokines</arm_group_label>
    <arm_group_label>Low levels of serum adipokines</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with locally advanced rectal cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with locally advanced rectal cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  below 18 years old&#xD;
&#xD;
          -  patients who did not received neoadjuvant therapyAll&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Cihad Tatar, MD</last_name>
    <phone>+905336599889</phone>
    <email>tatarcihad@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istanbul Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34029</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cihad Tatar</last_name>
      <phone>+905336599889</phone>
      <email>tatarcihad@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Husnu Sevik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Cihad Tatar</investigator_full_name>
    <investigator_title>Associate Profesor</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>serum adipokines</keyword>
  <keyword>leptin</keyword>
  <keyword>adiponectin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

